⌘K

Home/Filings/4/0001209191-17-054197

4//SEC Filing

Wiezorek Jeffrey 4

Accession 0001209191-17-054197

CIK 0001510580other

View on SEC.gov Company Profile

Filed

Sep 26, 8:00 PM ET

Accepted

Sep 27, 9:41 PM ET

Size

6.4 KB

Accession

0001209191-17-054197

Insider Transaction Report

Form 4

Period: 2017-09-25

Kite Pharma, Inc.KITE

Wiezorek Jeffrey

VP Clinical Development

Transactions

Award
Common Stock
2017-09-25+10,000→ 31,107 total
Sale
Common Stock
2017-09-25$179.66/sh−5,283$949,164→ 25,824 total

Footnotes (2)

[F1]Includes 36 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017.
[F2]The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Kite Pharma, Inc.

CIK 0001510580

Entity typeother

Related Parties

1

filerCIK 0001610823

Filing Metadata

Form type: 4
Filed: Sep 26, 8:00 PM ET
Accepted: Sep 27, 9:41 PM ET
Size: 6.4 KB

View on SEC.gov